UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 4, 2019

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Corbus Pharmaceuticals Holdings, Inc.

File No. 1-37348 - CF#37157

Corbus Pharmaceuticals Holdings, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on January 3, 2019.

Based on representations by Corbus Pharmaceuticals Holdings, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1

through January 3, 2029

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary